{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,3,30]],"date-time":"2026-03-30T19:07:44Z","timestamp":1774897664690,"version":"3.50.1"},"reference-count":17,"publisher":"Public Library of Science (PLoS)","issue":"6","license":[{"start":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T00:00:00Z","timestamp":1654819200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"the Seireikai Group, a health care facility group"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>The purpose of this study was to identify factors associated with the increase in the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike (S1) protein and neutralizing antibody titer following SARS-CoV-2 vaccination. This observational study was conducted among healthcare workers working for a private hospital group in Fukushima Prefecture, Japan. Two blood samples were obtained from each participant. The first sample was obtained before the first dose of BNT162b2 (Pfizer-BioNTech) vaccine, and a second sample was obtained approximately 6 weeks later. Immunoglobulin G (IgG) antibody against the SARS-CoV-2 spike (S1) protein, immunoglobulin M (IgM) antibody against SARS-CoV-2 N-protein, and neutralizing activity were measured using the chemiluminescent immunoassay with iFlash 3000. A total of 231 healthcare workers who agreed to participate, and were negative for anti-SARS-CoV-2 IgM antibodies at enrollment, were included in the analysis. All participants had elevated IgG antibodies and neutralizing activity above the cutoff values. A total of 174 (75.3%) and 208 (90.0%) participants experienced adverse reactions after the first and second vaccine doses, respectively. Younger age, female sex, not taking immunosuppressive or antipyretic analgesic medication regularly, a lack of local adverse reactions after the first dose, and the presence of adverse reactions (fever, muscle, and joint pain) after the second dose were associated with higher IgG antibody titers and neutralizing activity. Intake of analgesic antipyretic for adverse reactions to vaccines was not significantly associated with antibody and neutralizing activity titer production. Immune responses after vaccination may differ among individuals, and continued countermeasures to prevent SARS-CoV-2 infection are vital.<\/jats:p>","DOI":"10.1371\/journal.pone.0269917","type":"journal-article","created":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T17:35:15Z","timestamp":1654882515000},"page":"e0269917","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":27,"title":["Factors associated with anti-severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) spike protein antibody titer and neutralizing activity among healthcare workers following vaccination with the BNT162b2 vaccine"],"prefix":"10.1371","volume":"17","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-3442-3779","authenticated-orcid":true,"given":"Yurie","family":"Kobashi","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yuzo","family":"Shimazu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-1613-6968","authenticated-orcid":true,"given":"Takeshi","family":"Kawamura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yoshitaka","family":"Nishikawa","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Fumiya","family":"Omata","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yudai","family":"Kaneko","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tatsuhiko","family":"Kodama","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaharu","family":"Tsubokura","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"340","published-online":{"date-parts":[[2022,6,10]]},"reference":[{"key":"pone.0269917.ref001","doi-asserted-by":"crossref","first-page":"922","DOI":"10.1016\/S1473-3099(21)00344-3","article-title":"Global COVID-19 vaccine inequity","volume":"21","author":"T. Burki","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"pone.0269917.ref002","doi-asserted-by":"crossref","first-page":"585","DOI":"10.1056\/NEJMoa2108891","article-title":"Effectiveness of Covid-19 vaccines against the B.1.617.2 (Delta) variant","volume":"385","author":"J Lopez Bernal","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0269917.ref003","doi-asserted-by":"crossref","first-page":"E257","DOI":"10.1002\/ajh.26185","article-title":"Age-dependent and gender-dependent antibody responses against SARS-CoV-2 in health workers and octogenarians after vaccination with the BNT162b2 mRNA vaccine","volume":"96","author":"E Terpos","year":"2021","journal-title":"Am J Hematol"},{"key":"pone.0269917.ref004","doi-asserted-by":"crossref","first-page":"2204","DOI":"10.1001\/jama.2021.7489","article-title":"Antibody response to 2-dose SARS-CoV-2 mRNA vaccine series in solid organ transplant recipients","volume":"325","author":"BJ Boyarsky","year":"2021","journal-title":"JAMA"},{"key":"pone.0269917.ref005","article-title":"Antibody responses to BNT162b2 mRNA COVID-19 vaccine in 2,015 healthcare workers in a single tertiary referral hospital in Japan","author":"T Kageyama","year":"2021","journal-title":"medRxiv"},{"key":"pone.0269917.ref006","doi-asserted-by":"crossref","first-page":"2457","DOI":"10.1001\/jama.2021.7152","article-title":"Association between vaccination with BNT162b2 and incidence of symptomatic and asymptomatic SARS-CoV-2 infections among health care workers","volume":"325","author":"Y Angel","year":"2021","journal-title":"JAMA"},{"key":"pone.0269917.ref007","doi-asserted-by":"crossref","first-page":"1525","DOI":"10.1038\/s41591-021-01449-9","article-title":"Immune responses against SARS-CoV-2 variants after heterologous and homologous ChAdOx1 nCoV-19\/BNT162b2 vaccination","volume":"27","author":"J Barros-Martins","year":"2021","journal-title":"Nat Med"},{"key":"pone.0269917.ref008","unstructured":"University of Birmingham. Delaying second Pfizer vaccines to 12 weeks significantly increases antibody responses in older people, finds study; 2021. https:\/\/www.birmingham.ac.uk\/news\/latest\/2021\/05\/covid-pfizer-vaccination-interval-antibodyresponse.aspx#:~:text=The%20research%20found%20that%20extending,second%20vaccine%20at%20three%20weeks. [Accessed 1 August 2021]."},{"key":"pone.0269917.ref009","doi-asserted-by":"crossref","first-page":"661","DOI":"10.1056\/NEJMc2108861","article-title":"Three doses of an mRNA Covid-19 vaccine in solid-organ transplant recipients","volume":"385","author":"N Kamar","year":"2021","journal-title":"N Engl J Med"},{"key":"pone.0269917.ref010","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1016\/S0140-6736(21)01594-4","article-title":"Antibody response after second BNT162b2 dose in allogeneic HSCT recipients","volume":"398","author":"R Redjoul","year":"2021","journal-title":"Lancet"},{"key":"pone.0269917.ref011","unstructured":"Ministory of Health Labour and Welfare, Situation report. [Cited 1 August 2021]. https:\/\/www.mhlw.go.jp\/stf\/covid-19\/kokunainohasseijoukyou_00006.html; 2021."},{"key":"pone.0269917.ref012","unstructured":"F. Prefecture, Insidence of COVID-19. [Cited 1 August 2021]. https:\/\/www.pref.fukushima.lg.jp\/sec\/21045c\/fukushima-hasseijyoukyou.html. In: Fukushima Prefectire; 2021."},{"key":"pone.0269917.ref013","doi-asserted-by":"crossref","first-page":"107884","DOI":"10.1016\/j.intimp.2021.107884","article-title":"Seroprevalence of SARS-CoV-2 antibodies among hospital staff in rural Central Fukushima, Japan: A historical cohort study","volume":"98","author":"Y Kobashi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"pone.0269917.ref014","doi-asserted-by":"crossref","first-page":"107360","DOI":"10.1016\/j.intimp.2020.107360","article-title":"The difference between IgM and IgG antibody prevalence in different serological assays for COVID-19; lessons from the examination of healthcare workers","volume":"92","author":"Y Kobashi","year":"2021","journal-title":"Int Immunopharmacol"},{"key":"pone.0269917.ref015","doi-asserted-by":"crossref","first-page":"e04122","DOI":"10.1002\/ccr3.4122","article-title":"Mental distress in a clinical nurse due to a false-positive COVID-19 antibody test result during the COVID-19 epidemic in Japan: A case report","volume":"9","author":"Y Shimazu","year":"2021","journal-title":"Clin Case Rep"},{"key":"pone.0269917.ref016","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1038\/s41586-021-03738-2","article-title":"SARS-CoV-2 mRNA vaccines induce persistent human germinal centre responses","volume":"596","author":"JS Turner","year":"2021","journal-title":"Nature"},{"key":"pone.0269917.ref017","doi-asserted-by":"crossref","first-page":"1205","DOI":"10.1038\/s41591-021-01377-8","article-title":"Neutralizing antibody levels are highly predictive of immune protection from symptomatic SARS-CoV-2 infection","volume":"27","author":"DS Khoury","year":"2021","journal-title":"Nat Med"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269917","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2022,6,10]],"date-time":"2022-06-10T17:35:30Z","timestamp":1654882530000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0269917"}},"subtitle":[],"editor":[{"given":"Evy","family":"Yunihastuti","sequence":"first","affiliation":[],"role":[{"role":"editor","vocabulary":"crossref"}]}],"short-title":[],"issued":{"date-parts":[[2022,6,10]]},"references-count":17,"journal-issue":{"issue":"6","published-online":{"date-parts":[[2022,6,10]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0269917","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,6,10]]}}}